See the DrugPatentWatch profile for Polivy
Polivy (polatuzumab vedotin-piiq) is a cancer treatment developed by Genentech, a member of the Roche Group. It is a CD20-directed antibody-drug conjugate used in the treatment of certain types of lymphoma [1].
How does Polivy work?
Polivy is designed to target cancer cells and deliver a chemotherapy agent directly to them. The drug consists of an antibody that binds to the CD20 protein found on the surface of certain B-cell lymphomas. Once attached, the antibody-drug conjugate is internalized by the cancer cell, releasing a potent cytotoxic agent that kills the cell [2].
What types of cancer is Polivy approved for?
Polivy is approved for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that is relapsed or refractory, in combination with other chemotherapy agents [2]. It is also indicated for adult patients with previously untreated DLBCL, in combination with other treatments [3].
What is the patent status for Polivy?
Information regarding the patent status of Polivy can be found on DrugPatentWatch.com, which tracks patent expirations and exclusivity periods for pharmaceuticals [4]. Understanding patent timelines is crucial for predicting the potential market entry of generic or biosimilar versions of the drug.
Who are the competitors of Polivy?
The competitive landscape for DLBCL treatments includes other immunotherapies and chemotherapy regimens. Drugs like Rituxan (rituximab), also developed by Genentech/Roche, are widely used in lymphoma treatment and represent a significant comparator [5]. Other companies are also developing novel agents for relapsed or refractory DLBCL, contributing to a dynamic market.
What clinical trials have been conducted for Polivy?
Key clinical trials for Polivy include the GO29365 study, which evaluated its efficacy in relapsed or refractory DLBCL [2]. Another significant trial is the POLARIX study, assessing Polivy in previously untreated DLBCL [3]. These studies have provided the data supporting its regulatory approvals.
Are there any notable side effects associated with Polivy?
Common side effects reported with Polivy treatment can include neutropenia, thrombocytopenia, anemia, peripheral neuropathy, and fatigue. Patients and healthcare providers closely monitor for these and other potential adverse events during treatment [2].